查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1637054

全球祛痰药市场 - 全球产业分析、规模、占有率、成长、趋势及 2032 年预测

Expectorant Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032
出版日期: | 出版商: Fairfield Market Research | 英文 178 Pages | 商品交期: 2-5个工作天内

价格
简介目录

随着呼吸系统疾病盛行率的上升以及对有效症状管理认识的提高，全球祛痰药市场规模将显着成长。预计市场规模将以 4.20% 的复合年增长率成长，到 2025 年达到 182.4 亿美元，到 2032 年达到 243.2 亿美元。祛痰药在呼吸保健中发挥着至关重要的作用，可促进黏液清除并改善慢性阻塞性肺病 (COPD)、气喘和支气管炎等患者的呼吸舒适度。

痰萃取物可促进呼吸道黏液的清除，对治疗呼吸系统疾病至关重要。它能有效缓解咳嗽和鼻塞，是慢性和急性呼吸道照护的重要部分。药物配方的不断创新和先进药物输送机制的整合支撑了该市场的成长轨迹。

慢性阻塞性肺病和气喘等慢性疾病越来越普遍，推动了对祛痰药的需求。随着呼吸健康成为全球优先事项，这些药物正在成为症状管理的重要组成部分。人们越来越意识到早期有效症状管理的好处，从而推动了市场的成长。预防性保健实践强调及时使用祛痰药以避免併发症。製药公司正大力投入开发创新祛痰药物，进一步增加了市场潜力。

本报告研究了全球祛痰药市场，并提供了市场概述以及按药物类型、剂型、产品类型、分销渠道和地区划分的趋势信息，以及参与市场的公司的竞争动态。

目录

第 1 章执行摘要

第2章 市场概览

  • 市场定义与细分
  • 市场动态
  • 价值链分析
  • 波特五力分析
  • COVID-19 影响分析
  • PESTLE 分析

第3章 2025年价格分析

第 4 章2019 年至 2032 年北美祛痰药市场展望
  • 2019 年至 2032 年全球祛痰药市场预测（以药物类型、价值（十亿美元）、销售量（百万单位）
  • 2019 年至 2032 年全球祛痰药市场预测，依配方、价值（十亿美元）、销售量（百万单位）
  • 2019 年至 2032 年全球祛痰药市场展望（依产品类型、价值（十亿美元）、销售量（百万单位）
  • 2019 年至 2032 年全球祛痰药市场预测（按分销管道、价值（十亿美元）、销售（百万单位）
  • 2019 年至 2032 年全球祛痰药市场展望，依地区、价值（十亿美元）、销售量（百万单位）划分

第 5 章2019 年至 2032 年北美祛痰药市场展望

第6章 2019 年至 2032 年欧洲祛痰药市场展望

第 7 章 2019-2032 年亚太祛痰药市场展望

第 8 章2019 年至 2032 年拉丁美洲祛痰药市场展望

第 9 章2019 年至 2032 年中东及非洲祛痰药市场展望

第 10 章 竞争格局

  • 2025 年公司市占率分析
  • 竞争资讯中心
  • 公司简介
    • Abbott Laboratories
    • Acella Pharmaceuticals LLC
    • Astrazeneca Plc.
    • Cipla Limited
    • Dabur India Ltd
    • Glenmark Pharmaceuticals Limited
    • Johnson and Johnson
    • Merck KGaA
    • Novartis International AG
    • 他

第11章 附录

简介目录

The global expectorant drugs market is set to experience significant growth, driven by the increasing prevalence of respiratory disorders and heightened awareness regarding effective symptom management. With an anticipated expansion at a CAGR of 4.20%, the market is projected to reach USD 18.24 billion in 2025 and USD 24.32 billion by 2032. Expectorant drugs play a pivotal role in respiratory healthcare, facilitating mucus clearance and enhancing breathing comfort for patients dealing with conditions like chronic obstructive pulmonary disease (COPD), asthma, and bronchitis.

Market Insights Expectorant drugs are essential in managing respiratory ailments by promoting the expulsion of mucus from the respiratory tract. Their efficacy in alleviating coughs and congestion makes them indispensable in both chronic and acute respiratory care. The market's growth trajectory is bolstered by continuous innovation in drug formulations and the integration of advanced drug delivery mechanisms.

Key Market Drivers

  • 1. Rising Prevalence of Respiratory Disorders: Chronic conditions like COPD and asthma are increasingly common, driving demand for expectorant drugs. With respiratory health gaining priority globally, these medications are becoming a critical part of symptom management.
  • 2. Awareness of Early Intervention: Growing recognition of the benefits of early and effective symptom management is propelling market growth. Preventive healthcare practices emphasize the timely use of expectorant drugs to avoid complications.
  • 3. Research and Development Advancements: Pharmaceutical companies are investing heavily in the development of innovative expectorant formulations, further enhancing the market's potential.

Business Opportunities

  • 1. Innovative Formulations and Combination Therapies: The development of advanced drug delivery systems, such as extended-release formulations, offers promising revenue opportunities. Combination therapies incorporating expectorants with bronchodilators or anti-inflammatory agents can address multiple aspects of respiratory conditions.
  • 2. Targeted Products for Diverse Demographics: Companies can expand their product portfolios by developing specialized expectorant drugs tailored for pediatric, geriatric, and condition-specific needs. This diversification addresses a broader range of patient requirements and fosters market penetration.
  • 3. Expansion into Emerging Markets: Rapid urbanization and increasing healthcare awareness in regions like South Asia and the Pacific present lucrative opportunities for market growth.

Regional Analysis

  • 1. Europe: Europe holds a dominant position in the expectorant drugs market due to its robust healthcare infrastructure and high prevalence of respiratory disorders. Advanced medical facilities and proactive respiratory health management contribute to the region's strong foothold.
  • 2. South Asia and the Pacific: This region is anticipated to witness the fastest growth, driven by urbanization, environmental challenges, and an increasing burden of respiratory ailments. Enhanced healthcare access and rising awareness further support market expansion.
  • 3. North America and East Asia: These regions also show significant market potential, attributed to established pharmaceutical industries and growing healthcare expenditure.

Key Players The expectorant drugs market is characterized by intense competition among leading pharmaceutical companies. Notable players include:

  • Abbott Laboratories
  • Acella Pharmaceuticals LLC
  • AstraZeneca Plc.
  • Cipla Limited
  • Dabur India Ltd
  • Glenmark Pharmaceuticals Limited
  • Johnson & Johnson
  • Merck KGaA
  • Novartis International AG
  • Pfizer Inc.
  • Procter & Gamble Co.

These companies focus on strategic partnerships, innovative product launches, and geographical expansion to strengthen their market position.

Recent Developments

1. Product Launches:

    In October 2023, Efficient Laboratories introduced "ROMPR PECHITO," an OTC medicine designed for pediatric cold relief. In September 2023, Genexa launched new clean OTC kids' medicines, emphasizing safety and effectiveness, which resonated well with health-conscious consumers.

Market SegmentationThe expectorant drugs market can be categorized as follows:

1. By Drug Type:

    Secretion Enhancers: Includes potassium citrate, guaiphenesin, and ammonium chloride. Mucolytics: Comprising bromhexine, ambroxol, and acetyl cysteine.

2. By Dosage Form:

    Oral Solid: Tablets and capsules dominate due to patient convenience and precise dosing. Oral Liquid: Fast-acting formulations gaining popularity for rapid symptom relief. Inhalants: Preferred for targeted respiratory treatment.

3. By Product Type:

    Over-The-Counter (OTC): Leading segment due to accessibility and ease of use. Prescription Drugs: Essential for managing complex respiratory conditions.

4. By Distribution Channel:

    Hospital Pharmacies: Highest sales due to direct integration with healthcare facilities. Online Pharmacies: Fastest-growing segment, driven by digital convenience and accessibility. Retail Stores and Drug Stores: Continues to be a critical distribution channel.

5. By Region:

    North America Europe East Asia South Asia & Oceania Latin America Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Expectorant Drugs Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value and Volume, 2025
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. PESTLE Analysis

3. Price Analysis, 2025

  • 3.1. Global Average Price Analysis, by Drug Type/ Material, US$ Per Unit, 2025
  • 3.2. Prominent Factor Affecting Expectorant Drugs Prices
  • 3.3. Global Average Price Analysis, by Region, US$ Per Unit

4. Global Expectorant Drugs Market Outlook, 2019 - 2032

  • 4.1. Global Expectorant Drugs Market Outlook, by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 4.1.1. Key Highlights
      • 4.1.1.1. Secretion Enhancer
        • 4.1.1.1.1. Potassium Citrate
        • 4.1.1.1.2. Potassium Iodide
        • 4.1.1.1.3. Sodium Citrate
        • 4.1.1.1.4. Guaiphenesin
        • 4.1.1.1.5. Ammonium Chloride
        • 4.1.1.1.6. Others
      • 4.1.1.2. Mucolytics
        • 4.1.1.2.1. Bromhexine
        • 4.1.1.2.2. Ambroxol
        • 4.1.1.2.3. Acetyl Cysteine
        • 4.1.1.2.4. Carbocisteineurine
  • 4.2. Global Expectorant Drugs Market Outlook, by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 4.2.1. Key Highlights
      • 4.2.1.1. Oral Solid
      • 4.2.1.2. Oral Liquid
      • 4.2.1.3. Inhalant
  • 4.3. Global Expectorant Drugs Market Outlook, by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 4.3.1. Key Highlights
      • 4.3.1.1. Over The Counter (OTC)
      • 4.3.1.2. Prescription Drug
  • 4.4. Global Expectorant Drugs Market Outlook, by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 4.4.1. Key Highlights
      • 4.4.1.1. Hospital Pharmacies
      • 4.4.1.2. Retail Store
      • 4.4.1.3. Drug Store
      • 4.4.1.4. Online Pharmacies
  • 4.5. Global Expectorant Drugs Market Outlook, by Region, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 4.5.1. Key Highlights
      • 4.5.1.1. North America
      • 4.5.1.2. Europe
      • 4.5.1.3. Asia Pacific
      • 4.5.1.4. Latin America
      • 4.5.1.5. Middle East & Africa

5. North America Expectorant Drugs Market Outlook, 2019 - 2032

  • 5.1. North America Expectorant Drugs Market Outlook, by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 5.1.1. Key Highlights
      • 5.1.1.1. Secretion Enhancer
        • 5.1.1.1.1. Potassium Citrate
        • 5.1.1.1.2. Potassium Iodide
        • 5.1.1.1.3. Sodium Citrate
        • 5.1.1.1.4. Guaiphenesin
        • 5.1.1.1.5. Ammonium Chloride
        • 5.1.1.1.6. Others
      • 5.1.1.2. Mucolytics
        • 5.1.1.2.1. Bromhexine
        • 5.1.1.2.2. Ambroxol
        • 5.1.1.2.3. Acetyl Cysteine
        • 5.1.1.2.4. Carbocisteineurine
  • 5.2. North America Expectorant Drugs Market Outlook, by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 5.2.1. Key Highlights
      • 5.2.1.1. Oral Solid
      • 5.2.1.2. Oral Liquid
      • 5.2.1.3. Inhalant
  • 5.3. North America Expectorant Drugs Market Outlook, by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 5.3.1. Key Highlights
      • 5.3.1.1. Over The Counter (OTC)
      • 5.3.1.2. Prescription Drug
  • 5.4. North America Expectorant Drugs Market Outlook, by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 5.4.1. Key Highlights
      • 5.4.1.1. Hospital Pharmacies
      • 5.4.1.2. Retail Store
      • 5.4.1.3. Drug Store
      • 5.4.1.4. Online Pharmacies
  • 5.5. North America Expectorant Drugs Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 5.5.1. Key Highlights
      • 5.5.1.1. Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 5.5.1.2. Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 5.5.1.3. Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 5.5.1.4. Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 5.5.1.5. Canada Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 5.5.1.6. Canada Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 5.5.1.7. Canada Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 5.5.1.8. Canada Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Europe Expectorant Drugs Market Outlook, 2019 - 2032

  • 6.1. Europe Expectorant Drugs Market Outlook, by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 6.1.1. Key Highlights
      • 6.1.1.1. Secretion Enhancer
        • 6.1.1.1.1. Potassium Citrate
        • 6.1.1.1.2. Potassium Iodide
        • 6.1.1.1.3. Sodium Citrate
        • 6.1.1.1.4. Guaiphenesin
        • 6.1.1.1.5. Ammonium Chloride
        • 6.1.1.1.6. Others
      • 6.1.1.2. Mucolytics
        • 6.1.1.2.1. Bromhexine
        • 6.1.1.2.2. Ambroxol
        • 6.1.1.2.3. Acetyl Cysteine
        • 6.1.1.2.4. Carbocisteineurine
  • 6.2. Europe Expectorant Drugs Market Outlook, by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 6.2.1. Key Highlights
      • 6.2.1.1. Oral Solid
      • 6.2.1.2. Oral Liquid
      • 6.2.1.3. Inhalant
  • 6.3. Europe Expectorant Drugs Market Outlook, by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 6.3.1. Key Highlights
      • 6.3.1.1. Over The Counter (OTC)
      • 6.3.1.2. Prescription Drug
  • 6.4. Europe Expectorant Drugs Market Outlook, by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.4.1.1. Hospital Pharmacies
      • 6.4.1.2. Retail Store
      • 6.4.1.3. Drug Store
      • 6.4.1.4. Online Pharmacies
  • 6.5. Europe Expectorant Drugs Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 6.5.1. Key Highlights
      • 6.5.1.1. Germany Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.2. Germany Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.3. Germany Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.4. Germany Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.5. U.K. Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.6. U.K. Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.7. U.K. Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.8. U.K. Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.9. France Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.10. France Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.11. France Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.12. France Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.13. Italy Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.14. Italy Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.15. Italy Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.16. Italy Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.17. Turkey Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.18. Turkey Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.19. Turkey Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.20. Turkey Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.21. Russia Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.22. Russia Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.23. Russia Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.24. Russia Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.25. Rest of Europe Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.26. Rest of Europe Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.27. Rest of Europe Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.28. Rest of Europe Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Asia Pacific Expectorant Drugs Market Outlook, 2019 - 2032

  • 7.1. Asia Pacific Expectorant Drugs Market Outlook, by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.1.1. Key Highlights
      • 7.1.1.1. Secretion Enhancer
        • 7.1.1.1.1. Potassium Citrate
        • 7.1.1.1.2. Potassium Iodide
        • 7.1.1.1.3. Sodium Citrate
        • 7.1.1.1.4. Guaiphenesin
        • 7.1.1.1.5. Ammonium Chloride
        • 7.1.1.1.6. Others
      • 7.1.1.2. Mucolytics
        • 7.1.1.2.1. Bromhexine
        • 7.1.1.2.2. Ambroxol
        • 7.1.1.2.3. Acetyl Cysteine
        • 7.1.1.2.4. Carbocisteineurine
  • 7.2. Asia Pacific Expectorant Drugs Market Outlook, by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.2.1. Key Highlights
      • 7.2.1.1. Oral Solid
      • 7.2.1.2. Oral Liquid
      • 7.2.1.3. Inhalant
  • 7.3. Asia Pacific Expectorant Drugs Market Outlook, by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.3.1. Key Highlights
      • 7.3.1.1. Over The Counter (OTC)
      • 7.3.1.2. Prescription Drug
  • 7.4. Asia Pacific Expectorant Drugs Market Outlook, by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.4.1. Key Highlights
      • 7.4.1.1. Hospital Pharmacies
      • 7.4.1.2. Retail Store
      • 7.4.1.3. Drug Store
      • 7.4.1.4. Online Pharmacies
  • 7.5. Asia Pacific Expectorant Drugs Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.5.1. Key Highlights
      • 7.5.1.1. China Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.2. China Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.3. China Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.4. China Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.5. Japan Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.6. Japan Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.7. Japan Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.8. Japan Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.9. South Korea Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.10. South Korea Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.11. South Korea Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.12. South Korea Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.13. India Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.14. India Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.15. India Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.16. India Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.17. Southeast Asia Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.18. Southeast Asia Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.19. Southeast Asia Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.20. Southeast Asia Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.21. Rest of Asia Pacific Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.22. Rest of Asia Pacific Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.23. Rest of Asia Pacific Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.24. Rest of Asia Pacific Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Latin America Expectorant Drugs Market Outlook, 2019 - 2032

  • 8.1. Latin America Expectorant Drugs Market Outlook, by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 8.1.1. Key Highlights
      • 8.1.1.1. Secretion Enhancer
        • 8.1.1.1.1. Potassium Citrate
        • 8.1.1.1.2. Potassium Iodide
        • 8.1.1.1.3. Sodium Citrate
        • 8.1.1.1.4. Guaiphenesin
        • 8.1.1.1.5. Ammonium Chloride
        • 8.1.1.1.6. Others
      • 8.1.1.2. Mucolytics
        • 8.1.1.2.1. Bromhexine
        • 8.1.1.2.2. Ambroxol
        • 8.1.1.2.3. Acetyl Cysteine
        • 8.1.1.2.4. Carbocisteineurine
  • 8.2. Latin America Expectorant Drugs Market Outlook, by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.2.1.1. Oral Solid
      • 8.2.1.2. Oral Liquid
      • 8.2.1.3. Inhalant
  • 8.3. Latin America Expectorant Drugs Market Outlook, by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 8.3.1. Key Highlights
      • 8.3.1.1. Over The Counter (OTC)
      • 8.3.1.2. Prescription Drug
  • 8.4. Latin America Expectorant Drugs Market Outlook, by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 8.4.1. Key Highlights
      • 8.4.1.1. Hospital Pharmacies
      • 8.4.1.2. Retail Store
      • 8.4.1.3. Drug Store
      • 8.4.1.4. Online Pharmacies
  • 8.5. Latin America Expectorant Drugs Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 8.5.1. Key Highlights
      • 8.5.1.1. Brazil Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.2. Brazil Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.3. Brazil Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.4. Brazil Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.5. Mexico Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.6. Mexico Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.7. Mexico Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.8. Mexico Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.9. Argentina Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.10. Argentina Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.11. Argentina Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.12. Argentina Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.13. Rest of Latin America Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.14. Rest of Latin America Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.15. Rest of Latin America Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.16. Rest of Latin America Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Middle East & Africa Expectorant Drugs Market Outlook, 2019 - 2032

  • 9.1. Middle East & Africa Expectorant Drugs Market Outlook, by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.1.1. Key Highlights
      • 9.1.1.1. Secretion Enhancer
        • 9.1.1.1.1. Potassium Citrate
        • 9.1.1.1.2. Potassium Iodide
        • 9.1.1.1.3. Sodium Citrate
        • 9.1.1.1.4. Guaiphenesin
        • 9.1.1.1.5. Ammonium Chloride
        • 9.1.1.1.6. Others
      • 9.1.1.2. Mucolytics
        • 9.1.1.2.1. Bromhexine
        • 9.1.1.2.2. Ambroxol
        • 9.1.1.2.3. Acetyl Cysteine
        • 9.1.1.2.4. Carbocisteineurine
  • 9.2. Middle East & Africa Expectorant Drugs Market Outlook, by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.2.1. Key Highlights
      • 9.2.1.1. Oral Solid
      • 9.2.1.2. Oral Liquid
      • 9.2.1.3. Inhalant
  • 9.3. Middle East & Africa Expectorant Drugs Market Outlook, by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.3.1. Key Highlights
      • 9.3.1.1. Over The Counter (OTC)
      • 9.3.1.2. Prescription Drug
  • 9.4. Middle East & Africa Expectorant Drugs Market Outlook, by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.4.1. Key Highlights
      • 9.4.1.1. Hospital Pharmacies
      • 9.4.1.2. Retail Store
      • 9.4.1.3. Drug Store
      • 9.4.1.4. Online Pharmacies
  • 9.5. Middle East & Africa Expectorant Drugs Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.5.1. Key Highlights
      • 9.5.1.1. GCC Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.2. GCC Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.3. GCC Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.4. GCC Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.5. South Africa Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.6. South Africa Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.7. South Africa Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.8. South Africa Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.9. Egypt Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.10. Egypt Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.11. Egypt Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.12. Egypt Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.13. Nigeria Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.14. Nigeria Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.15. Nigeria Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.16. Nigeria Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.17. Rest of Middle East & Africa Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.18. Rest of Middle East & Africa Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.19. Rest of Middle East & Africa Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.20. Rest of Middle East & Africa Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.5.2. BPS Analysis/Market Attractiveness Analysis

10. Competitive Landscape

  • 10.1. Company Market Share Analysis, 2025
  • 10.2. Competitive Dashboard
  • 10.3. Company Profiles
    • 10.3.1. Abbott Laboratories
      • 10.3.1.1. Company Overview
      • 10.3.1.2. Product Portfolio
      • 10.3.1.3. Financial Overview
      • 10.3.1.4. Business Strategies and Development
    • 10.3.2. Acella Pharmaceuticals LLC
      • 10.3.2.1. Company Overview
      • 10.3.2.2. Product Portfolio
      • 10.3.2.3. Financial Overview
      • 10.3.2.4. Business Strategies and Development
    • 10.3.3. Astrazeneca Plc.
      • 10.3.3.1. Company Overview
      • 10.3.3.2. Product Portfolio
      • 10.3.3.3. Financial Overview
      • 10.3.3.4. Business Strategies and Development
    • 10.3.4. Cipla Limited
      • 10.3.4.1. Company Overview
      • 10.3.4.2. Product Portfolio
      • 10.3.4.3. Financial Overview
      • 10.3.4.4. Business Strategies and Development
    • 10.3.5. Dabur India Ltd
      • 10.3.5.1. Company Overview
      • 10.3.5.2. Product Portfolio
      • 10.3.5.3. Financial Overview
      • 10.3.5.4. Business Strategies and Development
    • 10.3.6. Glenmark Pharmaceuticals Limited
      • 10.3.6.1. Company Overview
      • 10.3.6.2. Product Portfolio
      • 10.3.6.3. Financial Overview
      • 10.3.6.4. Business Strategies and Development
    • 10.3.7. Johnson and Johnson
      • 10.3.7.1. Company Overview
      • 10.3.7.2. Product Portfolio
      • 10.3.7.3. Financial Overview
      • 10.3.7.4. Business Strategies and Development
    • 10.3.8. Merck KGaA
      • 10.3.8.1. Company Overview
      • 10.3.8.2. Product Portfolio
      • 10.3.8.3. Financial Overview
      • 10.3.8.4. Business Strategies and Development
    • 10.3.9. Novartis International AG
      • 10.3.9.1. Company Overview
      • 10.3.9.2. Product Portfolio
      • 10.3.9.3. Financial Overview
      • 10.3.9.4. Business Strategies and Development
    • 10.3.10. Others
      • 10.3.10.1. Company Overview
      • 10.3.10.2. Product Portfolio
      • 10.3.10.3. Financial Overview
      • 10.3.10.4. Business Strategies and Development

11. Appendix

  • 11.1. Research Methodology
  • 11.2. Report Assumptions
  • 11.3. Acronyms and Abbreviations